From the Pfizer/BioNTech and Oxford/AstraZeneca vaccines to GSK’s lifesaving antibody treatments, European innovation has played a crucial role in the global response to COVID-19.
But while the pandemic triggered a boom in biotech initial public offerings, according to Hannah Kuchler, Global Pharmaceuticals Correspondent at the Financial Times (FT), the vast majority went public on the US’ NASDAQ.
“It highlighted, yet again, concerns about whether fantastic academic science is as easy to translate into companies in Europe as it is in the United States, and questions about how to encourage follow-on capital that allows companies to stay at home,” she said, kicking off an FT panel discussion on how to support pharma innovation in Europe earlier this week.
